Phase I study of peptide vaccination for patients with biliary tract cancer

Phase I study of peptide vaccination for patients with biliary tract cancer - Phase I study of peptide vaccination for patients with biliary tract cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003207

Enrollment

Registered

2010-02-19

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary tract cancer

Interventions

Patients will be vaccinated once a week for four weeks of a treatment cycle. ON each vaccination day, the HLA-A*2402 restricted A1589 peptide(0.5mg), A3243 peptide(0.5mg), B5860N peptide(0.5mg), C745

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Clinically or pathologically diagnosed biliary tract cancer 2.Age between 20 to 80 3.Life expectancy > 3 months 4.No severe organ function impairment 5.Patients who have unresectable tumors to be refractory to chemotherapy 6.Written informed consent of the patient 7.Performance Status 0-2

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigator 3.Patient with severe underlying disease 4.Patient with severe allergy disease

Design outcomes

Primary

Measure	Time frame
Assessment of safety	—

Secondary

Measure	Time frame
Assessment of specific immune response	—

Countries

Japan

Contacts

Public ContactAtsushi Aruga

Tokyo Women's Medical University Institute of Advanced Biomedial Engineering and Science

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026